Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
- PMID: 37937763
- DOI: 10.1056/NEJMoa2306434
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Abstract
Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.
Methods: In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed.
Results: A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.
Conclusions: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).
Copyright © 2023 Massachusetts Medical Society.
Comment in
-
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.N Engl J Med. 2024 Feb 1;390(5):478. doi: 10.1056/NEJMc2314600. N Engl J Med. 2024. PMID: 38294983 No abstract available.
-
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.N Engl J Med. 2024 Feb 1;390(5):478-479. doi: 10.1056/NEJMc2314600. N Engl J Med. 2024. PMID: 38294984 No abstract available.
Similar articles
-
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
-
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Clinical Trial.
-
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Clinical Trial.
-
Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.J Oncol Pharm Pract. 2018 Jul;24(5):379-388. doi: 10.1177/1078155217712401. Epub 2017 May 31. J Oncol Pharm Pract. 2018. PMID: 28565936 Review.
-
Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.Medicine (Baltimore). 2023 Aug 25;102(34):e34545. doi: 10.1097/MD.0000000000034545. Medicine (Baltimore). 2023. PMID: 37653755 Free PMC article. Review.
Cited by
-
Drug development and evidence for lung cancer targeted therapy in Eastern Asia.Lancet Reg Health West Pac. 2024 Jul 8;49:101090. doi: 10.1016/j.lanwpc.2024.101090. eCollection 2024 Aug. Lancet Reg Health West Pac. 2024. PMID: 39381018 Free PMC article. Review.
-
Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result.Sci Rep. 2024 Oct 4;14(1):23115. doi: 10.1038/s41598-024-73749-2. Sci Rep. 2024. PMID: 39367090 Free PMC article. Clinical Trial.
-
Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics.Front Genet. 2024 Sep 19;15:1455502. doi: 10.3389/fgene.2024.1455502. eCollection 2024. Front Genet. 2024. PMID: 39364008 Free PMC article.
-
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.Sci Rep. 2024 Oct 2;14(1):22901. doi: 10.1038/s41598-024-74496-0. Sci Rep. 2024. PMID: 39358420 Free PMC article.
-
Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel). 2024 Sep 10;14(9):1142. doi: 10.3390/life14091142. Life (Basel). 2024. PMID: 39337925 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous